Insilico Medicine CEO to Discuss AI's Economic Potential at Fortune Global Forum 2024
核心洞察
Insilico Medicine (搜索)'s CEO, Alex Zhavoronkov, will participate in a Fortune Global Forum panel on November 12 to discuss AI's economic impact.
The panel will explore strategies for adopting AI at scale and leveraging its potential for economic growth and competitive advantages.
Insilico Medicine (搜索) has been integrating AI into its Pharma.AI (搜索) platform, nominating 19 preclinical candidates since 2021.
Insilico Medicine (搜索), a generative artificial intelligence (AI)-driven biotechnology company, announced that its founder and CEO, Alex Zhavoronkov, will be participating in the Fortune Global Forum 2024 in New York. Zhavoronkov will be part of a panel discussion titled “Rewiring Business: Unlocking AI’s Full Economic Potential” on November 12, focusing on strategies to adopt AI at speed and scale for economic growth and competitive advantage.
The Fortune Global Forum, an invite-only event, gathers leaders from the world’s largest multinational companies to discuss the future of global business. This year's forum will focus on creating a modern roadmap for success in a rapidly changing global landscape.
Insilico's AI-Driven Drug Discovery
Insilico Medicine (搜索) has been at the forefront of integrating AI into drug discovery and development. In 2016, the company first described the concept of using generative AI for novel molecule design. This work laid the foundation for the Pharma.AI (搜索) platform, a comprehensive solution spanning biology, chemistry, and clinical development.
Powered by Pharma.AI (搜索), Insilico has nominated 19 preclinical candidates across a portfolio of over 30 assets since 2021 and has received IND approval for 9 molecules. The company's lead drug pipeline, ISM001_055, is an AI-discovered target and AI-designed structure that has advanced to Phase II clinical trials. A recent publication in Nature Biotechnology detailed the entire R&D journey of ISM001_055, from AI algorithms to clinical trials.
Positive Phase IIa Trial Results for ISM001_055
Insilico Medicine (搜索) recently announced positive preliminary results from a Phase IIa trial (NCT05938920) of ISM001_055. The trial demonstrated a dose-dependent response in forced vital capacity (FVC) after only 12 weeks of dosage, suggesting potential efficacy in treating the disease investigated in the trial.